Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN® Commercialization
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, announced today it has completed its previously announced debt financing issuing a total of 7,744 units at a price of CDN $1,000 per unit for total ...